About teqcool

TEQCool AB is a medical technology company based in Lund, Sweden. TEQCool develops a unique, patented solution for selectively cooling the brain of patients with brain-injury suffering from neurogenic fever.

 

The intended therapy is based on many years of research and development at Lund University, pre-clinical and clinical studies as well as technical development by TEQCool’s engineers.

our VISION

BACKGROUND
5-6 million people suffer from severe TBI (Traumatic Brain Injury) per year with approximately 110 000 deaths in the US and Europe. Severely brain-injured patients with refractory fever, is a vulnerable patient group with poor prognosis. TEQCool’s main focus is severe TBI, where temperature control can both reduce fever and the intracranial pressure, to improve functional outcome, reduce mortality and length-of-hospital stay. This patient group is treated at Neuro-ICUs with cooling treatments poorly fitted to their needs.
 

OUR VISION

Preserve patients’ brain function with targeted brain temperature control. This we aim to
reach in strategic phases:

• develop and launch brain normothermia therapy for traumatic brain injury (TBI)
patients
 
• develop the therapy to fit patients that do not have an intracranial temperature
probe
 
• establish brain normothermia as gold standard across indications where
temperature control is established
 

Unique market opportunity

The global market for therapeutic temperature management is estimated to exceed 10 billion SEK per year.

 

The primary objective of temperature control is to preserve the patient’s neurogenic function. Existing systems cool the body in various ways and only secondarily the brain. TEQCool’s unique solution directly cools the brain via the nasal cavities. This selective and rapid brain cooling has the potential to transforming the temperature control market and establish a new treatment standard.

BOARD OF DIRECTORS

Ulf Bladin

Chairman

Ulf Bladin, Bachelor of Medicine from Karolinska Institutet, Master of Business Administration and Masters from the Stockholm School of Economics. Ulf has a long and solid career within medical technology and pharma, with senior positions within marketing and sales. He is now the CEO of Prolight Diagnostics AB and Board Member of Cardeon AB and Lumito AB.

BG Svensson
Member

BG Svensson, experienced board member in both listed and unlisted companies. BG has experience from leading positions in banking and industry and later as CEO of Lunds Universitets Holdingbolag, LUAB and Science Village Scandinavia AB.
He is now Chairman in SB1 Pharma AB and board member in NanoEcho AB, Reccan Diagnostics AB and Lumito AB.

Masoud Khayyami

Member

Masoud Khayyami, PhD in applied biochemistry from LTH, Lund University. Masoud has solid experience from research within medical technology and biotechnology. He is the principal owner and CEO of Cardeon AB.  Previously, he has been the CEO of SpectraCure AB.  Masoud has entrepreneurial experience in companies such as Lumito AB, Gasporox AB and Prolight Diagnostics AB.

Johan Ingemansson

Member

Johan Ingemansson has a master’s degree in Chemical Engineering with focus on Technology Management at Lund University. He has a long and broad experience within MedTech. Johan has previously held positions as VP Business Development in Etac and Director Strategic Planning in Gambro as well as management consultant at Roland Berger and Arthur D. Little. Johan is now the CEO of TEQCool AB.

MEDICAL ADVISOR

Niklas Marklund

MD, Ph.D. Professor of Neurosurgery at Dept of Clinical Sciences, Lund University, Sweden

Niklas Marklund, professor at the Department of Neurosurgery at Lund University, is new Medical Advisor for TEQCool. Professor Marklund is a leading expert in Traumatic Brain Injury and his clinical research involves the whole spectrum of the disease. He is the vice-president and co-founder of the European Neurotrauma Organisation (ENO), elected member of the Scandinavian Neurotrauma Committee and the Neurotrauma section of the World Federation of Neurological Surgery (WFNS), and the previous Trauma Section Chair (2017-2021) of the European Association of Neurosurgical Societies (EANS). Dr Marklund is on the editorial board of several scientific journals and a European editor of Journal of Neurotrauma.